CFO Wichterman sells 30,000 BLFS shares at $25.72; company facing -42.6% annual revenue decline and full-year unprofitability
Wichterman, CFO of BioLife Solutions, sold 30,000 shares (30.0K shares) at $25.72 on 2025-12-04, reducing his holdings by 16.4% to 152.8K shares and generating $771.6K in proceeds. The sale occurs in a context of material operational headwinds: annual revenue growth contracted -42.6% and the company posted negative net income over its most recent full fiscal year. His prior sell at this ticker on 2025-04-01 was followed by a 90-day return of -4.9%, marking a well-timed exit before a post-sale decline. The current trading environment shows the stock at $25.46, down 7.6% over the past 30 days, suggesting ongoing price pressure. A CFO's reduction of roughly one-sixth of his holdings during a period of significant revenue contraction and full-year unprofitability warrants investor attention to the underlying business trajectory.
CFO Troy Wichterman sold 25,687 shares (12.0% of holdings) at $22.66 as BLFS slides -21.2% from 52-week high amid -42.6% revenue decline
Troy Wichterman, Chief Financial Officer of BioLife Solutions, sold 25,687 shares on April 1, 2025, reducing his stake from 214,929 to 189,242 shares. The sale occurred at $22.66, representing a 12.0% reduction in his post-transaction holdings. The timing warrants attention: the stock has declined -21.2% from its 52-week high of $28.49 and is down -9.7% over the preceding 30 days, while the company faces significant operational headwinds including a -42.6% annual revenue decline and negative full-year net income of -$1.7M against $30.6M in latest-quarter revenue. A CFO's discretionary equity reduction during a period of material revenue contraction and depressed valuation may signal internal perspective on near-term business trajectory, though the sale does not necessarily reflect conviction about future price direction.
